Risk assessment
gliomas
RECURRENT CANCER, GLIOMAS
The ChemoID assay was classified as a non-significant risk assay for patients by the ethics committees. The current study utilized only sample specimens obtained by established procedures that patients undergo routinely for the treatment of his/her recurrent cancer; there was no additional risk to the patient. Tissue for this study was obtained by patient consent and after it was assured that there was adequate tissue for routine histologic analysis. At no time tissue was obtained solely for carrying out the ChemoID assay. No investigational agents were included in the trial. There were no greater than minimal risks associated with this study since all chemotherapy drugs used were FDA-approved for the treatment of recurrent 2016-WHO grade III or IV gliomas.